Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Equity Average (2016 - 2025)

Ligand Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $983.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 17.69% year-over-year to $983.7 million; the TTM value through Dec 2025 reached $983.7 million, up 17.69%, while the annual FY2025 figure was $923.8 million, 20.65% up from the prior year.
  • Equity Average for Q4 2025 was $983.7 million at Ligand Pharmaceuticals, up from $888.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $983.7 million in Q4 2025 and bottomed at $621.9 million in Q1 2023.
  • The 5-year median for Equity Average is $798.5 million (2021), against an average of $777.2 million.
  • The largest annual shift saw Equity Average decreased 22.95% in 2023 before it increased 22.12% in 2024.
  • A 5-year view of Equity Average shows it stood at $816.6 million in 2021, then decreased by 13.44% to $706.9 million in 2022, then dropped by 3.18% to $684.4 million in 2023, then grew by 22.12% to $835.8 million in 2024, then rose by 17.69% to $983.7 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Equity Average are $983.7 million (Q4 2025), $888.7 million (Q3 2025), and $811.5 million (Q2 2025).